These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

361 related items for PubMed ID: 27602501

  • 1. Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.
    Fernandes MS, Melo S, Velho S, Carneiro P, Carneiro F, Seruca R.
    Oncotarget; 2016 Oct 18; 7(42):68546-68558. PubMed ID: 27602501
    [Abstract] [Full Text] [Related]

  • 2. Pro-survival responses to the dual inhibition of anti-apoptotic Bcl-2 family proteins and mTOR-mediated signaling in hypoxic colorectal carcinoma cells.
    Risberg K, Redalen KR, Sønstevold L, Bjørnetrø T, Sølvernes J, Ree AH.
    BMC Cancer; 2016 Jul 26; 16():531. PubMed ID: 27461218
    [Abstract] [Full Text] [Related]

  • 3. Quadruple-editing of the MAPK and PI3K pathways effectively blocks the progression of KRAS-mutated colorectal cancer cells.
    Wang Z, Kang B, Gao Q, Huang L, Di J, Fan Y, Yu J, Jiang B, Gao F, Wang D, Sun H, Gu Y, Li J, Su X.
    Cancer Sci; 2021 Sep 26; 112(9):3895-3910. PubMed ID: 34185934
    [Abstract] [Full Text] [Related]

  • 4. The response of PIK3CA/KRAS-mutant colorectal cancer stem-like cells to RGD-peptide FraC produced by the strawberry anemone: A promising water-soluble peptide-based inhibitor of metastasis-driver gene CXCR4, stem cell regulatory genes and self-renewal.
    Sarkhosh-Inanlou R, Imani M, Sam MR.
    Biomed Pharmacother; 2020 Dec 26; 132():110807. PubMed ID: 33068939
    [Abstract] [Full Text] [Related]

  • 5. PI3K pathway dependencies in endometrioid endometrial cancer cell lines.
    Weigelt B, Warne PH, Lambros MB, Reis-Filho JS, Downward J.
    Clin Cancer Res; 2013 Jul 01; 19(13):3533-44. PubMed ID: 23674493
    [Abstract] [Full Text] [Related]

  • 6. Targeting the PI3K Signalling as a Therapeutic Strategy in Colorectal Cancer.
    Fernandes MS, Sanches JM, Seruca R.
    Adv Exp Med Biol; 2018 Jul 01; 1110():35-53. PubMed ID: 30623365
    [Abstract] [Full Text] [Related]

  • 7. Sorafenib enhances the therapeutic efficacy of rapamycin in colorectal cancers harboring oncogenic KRAS and PIK3CA.
    Gulhati P, Zaytseva YY, Valentino JD, Stevens PD, Kim JT, Sasazuki T, Shirasawa S, Lee EY, Weiss HL, Dong J, Gao T, Evers BM.
    Carcinogenesis; 2012 Sep 01; 33(9):1782-90. PubMed ID: 22696593
    [Abstract] [Full Text] [Related]

  • 8. Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers.
    Ebi H, Corcoran RB, Singh A, Chen Z, Song Y, Lifshits E, Ryan DP, Meyerhardt JA, Benes C, Settleman J, Wong KK, Cantley LC, Engelman JA.
    J Clin Invest; 2011 Nov 01; 121(11):4311-21. PubMed ID: 21985784
    [Abstract] [Full Text] [Related]

  • 9. Aspirin has a better effect on PIK3CA mutant colorectal cancer cells by PI3K/Akt/Raptor pathway.
    Chen Z, Wang C, Dong H, Wang X, Gao F, Zhang S, Zhang X.
    Mol Med; 2020 Jan 30; 26(1):14. PubMed ID: 32000660
    [Abstract] [Full Text] [Related]

  • 10. Novel small interfering RNA cotargeting strategy as treatment for colorectal cancer.
    Valentino JD, Elliott VA, Zaytseva YY, Rychahou PG, Mustain WC, Wang C, Gao T, Evers BM.
    Surgery; 2012 Aug 30; 152(2):277-85. PubMed ID: 22828149
    [Abstract] [Full Text] [Related]

  • 11. BRAF provides proliferation and survival signals in MSI colorectal carcinoma cells displaying BRAF(V600E) but not KRAS mutations.
    Preto A, Figueiredo J, Velho S, Ribeiro AS, Soares P, Oliveira C, Seruca R.
    J Pathol; 2008 Feb 30; 214(3):320-7. PubMed ID: 18098337
    [Abstract] [Full Text] [Related]

  • 12. LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer.
    Vakana E, Pratt S, Blosser W, Dowless M, Simpson N, Yuan XJ, Jaken S, Manro J, Stephens J, Zhang Y, Huber L, Peng SB, Stancato LF.
    Oncotarget; 2017 Feb 07; 8(6):9251-9266. PubMed ID: 27999210
    [Abstract] [Full Text] [Related]

  • 13. Coexistent mutations of KRAS and PIK3CA affect the efficacy of NVP-BEZ235, a dual PI3K/MTOR inhibitor, in regulating the PI3K/MTOR pathway in colorectal cancer.
    Kim A, Lee JE, Lee SS, Kim C, Lee SJ, Jang WS, Park S.
    Int J Cancer; 2013 Aug 15; 133(4):984-96. PubMed ID: 23475782
    [Abstract] [Full Text] [Related]

  • 14. The Safe Soluble Compound Dehydroascorbic Acid Inhibits Various Upstream and Downstream Effectors of PI3K and KRAS Signaling Pathways in Undruggable PIK3CA/KRAS-Mutant Colorectal Cancer Stem-Like Cells.
    Kalbkhani F, Pirnejad A, Sam S, Sam MR.
    Nutr Cancer; 2021 Aug 15; 73(11-12):2654-2664. PubMed ID: 33283545
    [Abstract] [Full Text] [Related]

  • 15. PDEδ inhibition impedes the proliferation and survival of human colorectal cancer cell lines harboring oncogenic KRas.
    Klein CH, Truxius DC, Vogel HA, Harizanova J, Murarka S, Martín-Gago P, Bastiaens PIH.
    Int J Cancer; 2019 Feb 15; 144(4):767-776. PubMed ID: 30194764
    [Abstract] [Full Text] [Related]

  • 16. BYL719, a selective inhibitor of phosphoinositide 3-Kinase α, enhances the effect of selumetinib (AZD6244, ARRY-142886) in KRAS-mutant non-small cell lung cancer.
    Ku BM, Jho EH, Bae YH, Sun JM, Ahn JS, Park K, Ahn MJ.
    Invest New Drugs; 2015 Feb 15; 33(1):12-21. PubMed ID: 25342139
    [Abstract] [Full Text] [Related]

  • 17. PI3K regulation of RAC1 is required for KRAS-induced pancreatic tumorigenesis in mice.
    Wu CY, Carpenter ES, Takeuchi KK, Halbrook CJ, Peverley LV, Bien H, Hall JC, DelGiorno KE, Pal D, Song Y, Shi C, Lin RZ, Crawford HC.
    Gastroenterology; 2014 Dec 15; 147(6):1405-16.e7. PubMed ID: 25311989
    [Abstract] [Full Text] [Related]

  • 18. KRAS mutated colorectal cancers with or without PIK3CA mutations: Clinical and molecular profiles inform current and future therapeutics.
    Voutsadakis IA.
    Crit Rev Oncol Hematol; 2023 Jun 15; 186():103987. PubMed ID: 37059275
    [Abstract] [Full Text] [Related]

  • 19. Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers.
    Temraz S, Mukherji D, Shamseddine A.
    Int J Mol Sci; 2015 Sep 23; 16(9):22976-88. PubMed ID: 26404261
    [Abstract] [Full Text] [Related]

  • 20. NG25, a novel inhibitor of TAK1, suppresses KRAS-mutant colorectal cancer growth in vitro and in vivo.
    Ma Q, Gu L, Liao S, Zheng Y, Zhang S, Cao Y, Zhang J, Wang Y.
    Apoptosis; 2019 Feb 23; 24(1-2):83-94. PubMed ID: 30515612
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.